Cayuga Biotech is an early-stage platform biotechnology company harnessing the body's innate ability to halt bleeding and heal. Cayuga's core proprietary technology leverages a recently discovered modulator of the coagulation response. The lead biomimetic drug addresses life-threatening hemorrhage in white space indications and is in preclinical development. Cayuga also has discovery stage programs in rare inherited bleeding disorders, platelet dysfunction, traumatic brain injury, severe burn and wound healing.